This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q65333930
rdf:type
wikibase:Item
schema:description
ensayu clínicu klinisch onderzoek clinical trial клінічне випробування
rdfs:label
Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers. Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.
skos:prefLabel
Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers. Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.
schema:name
Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers. Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.
p:P1476
wds:Q65333930-030F2708-53AD-4B0B-8124-2CCD251AE178
wdt:P1476
A PHASE 2, RANDOMIZED, CONTROLLED, OBSERVER-BLINDED STUDY CONDUCTED TO DESCRIBE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A NEISSERIA MENINGITIDIS SEROGROUP B BIVALENT RECOMBINANT LIPOPROTEIN 2086 VACCINE (BIVALENT RLP2086) WHEN ADMINISTERED TO HEALTHY TODDLERS AGED 12 TO <18 MONTHS OR 18 TO <24 MONTHS, AND THE SAFETY AND IMMUNOGENICITY OF A BOOSTER DOSE OF BIVALENT RLP2086
p:P582
wds:Q65333930-051BB353-33E1-4354-821A-4B75619D8C32
wdt:P582
2017-08-21T00:00:00Z
p:P31
wds:Q65333930-B6D806E2-D356-4E6A-902A-2994CA0E8318
wdt:P31
wd:Q30612
p:P2283
wds:Q65333930-7F53F65A-EA00-451B-AFA8-459674E98888
wdt:P2283
wd:Q73214260
p:P580
wds:Q65333930-1BBD0030-8BA7-454E-97A8-D932258A7BFC
wdt:P580
2015-08-31T00:00:00Z
p:P17
wds:Q65333930-9835A4C0-70A0-47B2-8AAB-ABD9F0ECB900 wds:Q65333930-47812C0E-F875-4BD8-9365-A2D305FEC04B wds:Q65333930-9C662D76-7A6C-4CD7-8AA7-C0AE015BDFEE
wdt:P17
wd:Q408 wd:Q36 wd:Q33
p:P921
wds:Q65333930-E388A2AF-7964-4934-A774-E31E4866DCCE
wdt:P921
wd:Q154625
p:P6153
wds:Q65333930-1A83F97D-F1D1-43CA-8C92-E1E192C51828 wds:Q65333930-458F6DFD-7A46-43BD-8866-5BEF9F0D11A8
wdt:P6153
wd:Q7244698 wd:Q22669992
p:P2899
wds:Q65333930-7BBC1FEB-499C-4496-910F-A9740D142642
wdt:P2899
12
p:P859
wds:Q65333930-13AC0045-91AD-44B9-81BA-19BA7090C85F
wdt:P859
wd:Q206921
p:P1132
wds:Q65333930-D36E8458-BEF4-497A-97D7-336B2092A304
wdt:P1132
398
p:P4135
wds:Q65333930-3F0F2DD6-6C5A-43A3-AE8B-B7A36ED85F94
wdt:P4135
24
p:P8363
wds:Q65333930-08D05EED-AB5A-42D7-8864-C40ED8063DC1
wdt:P8363
wd:Q78089383
p:P3098
wds:Q65333930-076BB22A-9DEA-4B0D-B712-175D67E1FB48
wdt:P3098
NCT02534935
p:P6099
wds:Q65333930-C8978F6E-7F9F-499D-88B4-934AE1DF8634
wdt:P6099
wd:Q42824440